Jeffrey Tong, Ph.D., has served as a member of our board of directors since February 2018. Dr. Tong is currently a Partner at Third Rock Ventures, a venture capital firm, where he has worked since May 2016. In addition to serving on the Nurix board, Dr. Tong currently serves on the boards of Maze Therapeutics, Ambys Medicines, Asher Bio, and several other private companies. From January 2016 to January 2017, Dr. Tong served as Executive Chairman of the Board of Delinia, Inc. (acquired by Celgene Corporation in 2017), a biotechnology company focused on autoimmune diseases. Dr. Tong served as President and Chief Executive Officer of Nora Therapeutics Inc. from 2010 to 2015 and was a member of the executive team of Infinity Pharmaceuticals, Inc. from 2001 to 2010. Dr. Tong holds an A.B. in Biochemistry from Harvard College, an M.M.S from Harvard Medical School, and an A.M. and Ph.D. in Chemistry from Harvard University.